NeuroPace Inc is a medical technology company that specializes in developing innovative neuromodulation devices aimed at transforming the treatment of neurological disorders. The company's flagship product is an implantable brain device that delivers responsive neurostimulation to manage epilepsy, helping patients who do not achieve adequate control with traditional medication. By continuously monitoring brain activity, NeuroPace's technology can provide targeted therapy in real-time, resulting in improved quality of life for individuals suffering from chronic seizures. Committed to advancing research and patient care, NeuroPace is at the forefront of personalized medicine in the neurological field. Read More
MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
MOUNTAIN VIEW, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30am PT (10:30am ET) on Thursday, January 10, 2024, in San Francisco, CA as well as host investor meetings prior to and during the conference.
First of its kind, multi-year collaboration leverages RNS System’s data to track responses of implanted RNS System patients enrolled in a biotechnology company’s clinical trial
